[
    {
        "id": 9064,
        "drug_name": "Altuviiio (Efanesoctocog alfa) - (XTEND-1)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Hemophilia A",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-02-23",
        "link": "https:\/\/www.globenewswire.com\/news-release\/2023\/02\/23\/2614759\/0\/en\/Press-Release-FDA-approves-once-weekly-ALTUVIIIO-a-new-class-of-factor-VIII-therapy-for-hemophilia-A-that-offers-significant-bleed-protection.html",
        "note": "Approved February 23, 2023.",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": [
            {
                "label": "Breakthrough Therapy Designation (BTD)",
                "abbreviation": "BTD",
                "description": "Breakthrough Therapy Designation (BTD)",
                "description_html": "<p>Breakthrough Therapy Designation (BTD)<\/p>\n"
            }
        ]
    },
    {
        "id": 10214,
        "drug_name": "Kevzara (sarilumab)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Polymyalgia rheumatica (PMR)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-02-28",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/REGN\/news\/119799",
        "note": "Approved February 28, 2023.",
        "company_entity_id": 388,
        "company_ticker": "REGN",
        "company_name": "Regeneron Pharmaceuticals Inc.",
        "company_price": "970.5700",
        "company_change": 6.13,
        "company_percent_change": 0.64,
        "company_optionable": 1,
        "company_number_of_shares": 109761896,
        "price_change_sparkline": [
            [
                942.78,
                1706677200
            ],
            [
                957.78,
                1706763600
            ],
            [
                945.18,
                1706850000
            ],
            [
                936.33,
                1707109200
            ],
            [
                937.81,
                1707195600
            ],
            [
                938.49,
                1707282000
            ],
            [
                946.43,
                1707368400
            ],
            [
                953.42,
                1707454800
            ],
            [
                947.06,
                1707714000
            ],
            [
                940.48,
                1707800400
            ],
            [
                947.82,
                1707886800
            ],
            [
                954.73,
                1707973200
            ],
            [
                948.05,
                1708059600
            ],
            [
                946.87,
                1708405200
            ],
            [
                952.84,
                1708491600
            ],
            [
                964.89,
                1708578000
            ],
            [
                981.2,
                1708664400
            ],
            [
                989.28,
                1708923600
            ],
            [
                993.35,
                1709010000
            ],
            [
                987.61,
                1709096400
            ],
            [
                966.09,
                1709182800
            ],
            [
                982.82,
                1709269200
            ],
            [
                971.19,
                1709528400
            ],
            [
                965.21,
                1709614800
            ],
            [
                972.1,
                1709701200
            ],
            [
                973.31,
                1709787600
            ],
            [
                968.83,
                1709874000
            ],
            [
                964.44,
                1710129600
            ],
            [
                970.57,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10226,
        "drug_name": "Verzenio (abemaciclib)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "HR+, HER2-, Node-Positive, High Risk Early Breast Cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-03-03",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/LLY\/news\/120696",
        "note": "Approved March 3, 2023.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10230,
        "drug_name": "MMRV Family Vaccines (Intramuscular Administration)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Measles, Mumps, and Rubella Virus Vaccine Live",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-03-06",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/MRK\/news\/120859",
        "note": "Approved March 6, 2023.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4100,
        "drug_name": "CHS-1701",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Pegfilgrastim biosimilar",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-03-06",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/CHRS\/news\/120923",
        "note": "Autoinjector approved March 6, 2023.",
        "company_entity_id": 89,
        "company_ticker": "CHRS",
        "company_name": "Coherus BioSciences Inc.",
        "company_price": "2.2400",
        "company_change": -0.030000000000000027,
        "company_percent_change": -1.3199999999999998,
        "company_optionable": 1,
        "company_number_of_shares": 111364152,
        "price_change_sparkline": [
            [
                2.15,
                1706677200
            ],
            [
                2.09,
                1706763600
            ],
            [
                2.06,
                1706850000
            ],
            [
                2.02,
                1707109200
            ],
            [
                2.32,
                1707195600
            ],
            [
                2.32,
                1707282000
            ],
            [
                2.38,
                1707368400
            ],
            [
                2.62,
                1707454800
            ],
            [
                2.82,
                1707714000
            ],
            [
                2.56,
                1707800400
            ],
            [
                2.72,
                1707886800
            ],
            [
                2.85,
                1707973200
            ],
            [
                2.76,
                1708059600
            ],
            [
                2.59,
                1708405200
            ],
            [
                2.48,
                1708491600
            ],
            [
                2.47,
                1708578000
            ],
            [
                2.58,
                1708664400
            ],
            [
                2.5,
                1708923600
            ],
            [
                2.62,
                1709010000
            ],
            [
                2.36,
                1709096400
            ],
            [
                2.28,
                1709182800
            ],
            [
                2.41,
                1709269200
            ],
            [
                2.27,
                1709528400
            ],
            [
                2.18,
                1709614800
            ],
            [
                2.21,
                1709701200
            ],
            [
                2.21,
                1709787600
            ],
            [
                2.39,
                1709874000
            ],
            [
                2.27,
                1710129600
            ],
            [
                2.24,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3063,
        "drug_name": "Naloxone Intranasal",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Opioid overdose",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-03-07",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/AMPH\/news\/121562",
        "note": "Approved March 8, 2023.",
        "company_entity_id": 363,
        "company_ticker": "AMPH",
        "company_name": "Amphastar Pharmaceuticals Inc.",
        "company_price": "44.1500",
        "company_change": 0.34,
        "company_percent_change": 0.78,
        "company_optionable": 1,
        "company_number_of_shares": 48095862,
        "price_change_sparkline": [
            [
                53.36,
                1706677200
            ],
            [
                53.49,
                1706763600
            ],
            [
                52.8,
                1706850000
            ],
            [
                52.35,
                1707109200
            ],
            [
                52.49,
                1707195600
            ],
            [
                52.96,
                1707282000
            ],
            [
                54.6,
                1707368400
            ],
            [
                55.61,
                1707454800
            ],
            [
                56.02,
                1707714000
            ],
            [
                54.75,
                1707800400
            ],
            [
                54.93,
                1707886800
            ],
            [
                55.51,
                1707973200
            ],
            [
                54.06,
                1708059600
            ],
            [
                52.45,
                1708405200
            ],
            [
                51.25,
                1708491600
            ],
            [
                51.91,
                1708578000
            ],
            [
                53.41,
                1708664400
            ],
            [
                55.09,
                1708923600
            ],
            [
                55.44,
                1709010000
            ],
            [
                54.74,
                1709096400
            ],
            [
                46.57,
                1709182800
            ],
            [
                46.22,
                1709269200
            ],
            [
                46.68,
                1709528400
            ],
            [
                47.33,
                1709614800
            ],
            [
                46.31,
                1709701200
            ],
            [
                46.76,
                1709787600
            ],
            [
                45.67,
                1709874000
            ],
            [
                43.81,
                1710129600
            ],
            [
                44.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7821,
        "drug_name": "Intranasal zavegepant",
        "clinical_trial_id": "NCT04571060",
        "has_trial_insight_page": 0,
        "indication": "Migraine",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-03-10",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/PFE\/news\/122186",
        "note": "Approved March 10, 2023.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10244,
        "drug_name": "Polivy (polatuzumab vedotin-piiq) in combination with Rituxan",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Diffuse Large B-Cell Lymphoma",
        "label": "BLA Filing",
        "value": "blaFiling",
        "simplified_stage": "phase4",
        "stageid": 12,
        "stage_name": "BLA Filing",
        "date": "2023-03-10",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/RHHBY\/news\/122142",
        "note": "Advisory committee meeting voted 11 to 2 in favor of approval, noted March 10, 2023.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5536,
        "drug_name": "DAYBUE (trofinetide)",
        "clinical_trial_id": "NCT04181723",
        "has_trial_insight_page": 0,
        "indication": "Rett Syndrome",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-03-10",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ACAD\/news\/122354",
        "note": "Approved March 10, 2023.",
        "company_entity_id": 5,
        "company_ticker": "ACAD",
        "company_name": "ACADIA Pharmaceuticals Inc.",
        "company_price": "19.9800",
        "company_change": -4.15,
        "company_percent_change": -17.2,
        "company_optionable": 1,
        "company_number_of_shares": 164771521,
        "price_change_sparkline": [
            [
                25.91,
                1706677200
            ],
            [
                26.14,
                1706763600
            ],
            [
                25.29,
                1706850000
            ],
            [
                25.1,
                1707109200
            ],
            [
                25.74,
                1707195600
            ],
            [
                25.21,
                1707282000
            ],
            [
                25.68,
                1707368400
            ],
            [
                26.36,
                1707454800
            ],
            [
                26.76,
                1707714000
            ],
            [
                25.56,
                1707800400
            ],
            [
                25.56,
                1707886800
            ],
            [
                25.18,
                1707973200
            ],
            [
                25.11,
                1708059600
            ],
            [
                24.85,
                1708405200
            ],
            [
                24.87,
                1708491600
            ],
            [
                24.85,
                1708578000
            ],
            [
                24.78,
                1708664400
            ],
            [
                25.9,
                1708923600
            ],
            [
                26.36,
                1709010000
            ],
            [
                23.745,
                1709096400
            ],
            [
                23.24,
                1709182800
            ],
            [
                24.01,
                1709269200
            ],
            [
                23.75,
                1709528400
            ],
            [
                23.81,
                1709614800
            ],
            [
                23.2,
                1709701200
            ],
            [
                23.52,
                1709787600
            ],
            [
                23.44,
                1709874000
            ],
            [
                24.13,
                1710129600
            ],
            [
                19.98,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10260,
        "drug_name": "Tafinlar (dabrafenib) + Mekinist (trametinib)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Pediatric BRAF V600E low-grade glioma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-03-17",
        "link": "https:\/\/www.novartis.com\/news\/media-releases\/novartis-tafinlar-mekinist-approved-fda-pediatric-patients-braf-v600e-low-grade-glioma-most-common-pediatric-brain-cancer",
        "note": "Approved March 17, 2023.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9580,
        "drug_name": "Hyrimoz (adalimumab-adaz) - (Humira biosimilar)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn\u2019s disease, ulcerative colitis, and plaque psoriasis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-03-21",
        "link": "https:\/\/www.novartis.com\/news\/media-releases\/sandoz-receives-us-fda-approval-biosimilar-hyrimoz-adalimumab-adaz-high-concentration-formulation",
        "note": "Approved March 21, 2023.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9407,
        "drug_name": "Evkeeza (evinacumab)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Homozygous familial hypercholesterolemia (HoFH) in children",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-03-22",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/REGN\/news\/124706",
        "note": "Approved March 22, 2023.",
        "company_entity_id": 388,
        "company_ticker": "REGN",
        "company_name": "Regeneron Pharmaceuticals Inc.",
        "company_price": "970.5700",
        "company_change": 6.13,
        "company_percent_change": 0.64,
        "company_optionable": 1,
        "company_number_of_shares": 109761896,
        "price_change_sparkline": [
            [
                942.78,
                1706677200
            ],
            [
                957.78,
                1706763600
            ],
            [
                945.18,
                1706850000
            ],
            [
                936.33,
                1707109200
            ],
            [
                937.81,
                1707195600
            ],
            [
                938.49,
                1707282000
            ],
            [
                946.43,
                1707368400
            ],
            [
                953.42,
                1707454800
            ],
            [
                947.06,
                1707714000
            ],
            [
                940.48,
                1707800400
            ],
            [
                947.82,
                1707886800
            ],
            [
                954.73,
                1707973200
            ],
            [
                948.05,
                1708059600
            ],
            [
                946.87,
                1708405200
            ],
            [
                952.84,
                1708491600
            ],
            [
                964.89,
                1708578000
            ],
            [
                981.2,
                1708664400
            ],
            [
                989.28,
                1708923600
            ],
            [
                993.35,
                1709010000
            ],
            [
                987.61,
                1709096400
            ],
            [
                966.09,
                1709182800
            ],
            [
                982.82,
                1709269200
            ],
            [
                971.19,
                1709528400
            ],
            [
                965.21,
                1709614800
            ],
            [
                972.1,
                1709701200
            ],
            [
                973.31,
                1709787600
            ],
            [
                968.83,
                1709874000
            ],
            [
                964.44,
                1710129600
            ],
            [
                970.57,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8480,
        "drug_name": "Zynyz (retifanlimab)",
        "clinical_trial_id": "NCT03599713",
        "has_trial_insight_page": 1,
        "indication": "Merkel cell carcinoma (MCC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-03-22",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/INCY\/news\/124860",
        "note": "FDA Approved on March 22, 2023.",
        "company_entity_id": 167,
        "company_ticker": "INCY",
        "company_name": "Incyte Corporation",
        "company_price": "59.3300",
        "company_change": -1.46,
        "company_percent_change": -2.4,
        "company_optionable": 1,
        "company_number_of_shares": 224526128,
        "price_change_sparkline": [
            [
                58.77,
                1706677200
            ],
            [
                59.16,
                1706763600
            ],
            [
                58.35,
                1706850000
            ],
            [
                58.06,
                1707109200
            ],
            [
                59.63,
                1707195600
            ],
            [
                57.34,
                1707282000
            ],
            [
                57.36,
                1707368400
            ],
            [
                57.66,
                1707454800
            ],
            [
                57.84,
                1707714000
            ],
            [
                59.34,
                1707800400
            ],
            [
                57.89,
                1707886800
            ],
            [
                58.97,
                1707973200
            ],
            [
                57.96,
                1708059600
            ],
            [
                58.82,
                1708405200
            ],
            [
                60.33,
                1708491600
            ],
            [
                60.91,
                1708578000
            ],
            [
                60.59,
                1708664400
            ],
            [
                60.53,
                1708923600
            ],
            [
                61,
                1709010000
            ],
            [
                59.98,
                1709096400
            ],
            [
                58.36,
                1709182800
            ],
            [
                59.05,
                1709269200
            ],
            [
                59.72,
                1709528400
            ],
            [
                58.9,
                1709614800
            ],
            [
                59.26,
                1709701200
            ],
            [
                59.03,
                1709787600
            ],
            [
                60.02,
                1709874000
            ],
            [
                60.79,
                1710129600
            ],
            [
                59.33,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3435,
        "drug_name": "REZZAYO (rezafungin injection)",
        "clinical_trial_id": "NCT03667690",
        "has_trial_insight_page": 0,
        "indication": "Candidemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-03-22",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/CDTX\/news\/124926",
        "note": "FDA approval on March 22, 2023.",
        "company_entity_id": 83,
        "company_ticker": "CDTX",
        "company_name": "Cidara Therapeutics Inc.",
        "company_price": "0.6839",
        "company_change": 0.02,
        "company_percent_change": 3.46,
        "company_optionable": 1,
        "company_number_of_shares": 90433777,
        "price_change_sparkline": [
            [
                0.6412,
                1706677200
            ],
            [
                0.654,
                1706763600
            ],
            [
                0.699,
                1706850000
            ],
            [
                0.6699,
                1707109200
            ],
            [
                0.6711,
                1707195600
            ],
            [
                0.6552,
                1707282000
            ],
            [
                0.671,
                1707368400
            ],
            [
                0.728,
                1707454800
            ],
            [
                0.705,
                1707714000
            ],
            [
                0.6801,
                1707800400
            ],
            [
                0.679,
                1707886800
            ],
            [
                0.6923,
                1707973200
            ],
            [
                0.7149,
                1708059600
            ],
            [
                0.709,
                1708405200
            ],
            [
                0.69,
                1708491600
            ],
            [
                0.691,
                1708578000
            ],
            [
                0.7,
                1708664400
            ],
            [
                0.7193,
                1708923600
            ],
            [
                0.7287,
                1709010000
            ],
            [
                0.7202,
                1709096400
            ],
            [
                0.7075,
                1709182800
            ],
            [
                0.7122,
                1709269200
            ],
            [
                0.707,
                1709528400
            ],
            [
                0.6999,
                1709614800
            ],
            [
                0.6993,
                1709701200
            ],
            [
                0.683,
                1709787600
            ],
            [
                0.691,
                1709874000
            ],
            [
                0.661,
                1710129600
            ],
            [
                0.6839,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9837,
        "drug_name": "Leniolisib",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Activated phosphoinositide 3-kinase delta syndrome (APDS)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-03-24",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/PHAR\/news\/125411",
        "note": "Approved March 24, 2023.",
        "company_entity_id": 1533,
        "company_ticker": "PHAR",
        "company_name": "Pharming Group N.V.",
        "company_price": "11.8800",
        "company_change": 0.23,
        "company_percent_change": 1.97,
        "company_optionable": 0,
        "company_number_of_shares": 65917843,
        "price_change_sparkline": [
            [
                12.75,
                1706677200
            ],
            [
                12.42,
                1706763600
            ],
            [
                13.0382,
                1706850000
            ],
            [
                12.2299,
                1707109200
            ],
            [
                12.2299,
                1707195600
            ],
            [
                12.93,
                1707282000
            ],
            [
                12,
                1707368400
            ],
            [
                11.2,
                1707454800
            ],
            [
                13.2,
                1707714000
            ],
            [
                11.4,
                1707800400
            ],
            [
                11.5591,
                1707886800
            ],
            [
                11.0301,
                1707973200
            ],
            [
                11.2,
                1708059600
            ],
            [
                11.01,
                1708405200
            ],
            [
                11.1393,
                1708491600
            ],
            [
                11.75,
                1708578000
            ],
            [
                11.75,
                1708664400
            ],
            [
                11.28,
                1708923600
            ],
            [
                11.16,
                1709010000
            ],
            [
                11.1,
                1709096400
            ],
            [
                11.4499,
                1709182800
            ],
            [
                11.3688,
                1709269200
            ],
            [
                11.79,
                1709528400
            ],
            [
                11.16,
                1709614800
            ],
            [
                11.2,
                1709701200
            ],
            [
                11.2,
                1709787600
            ],
            [
                11.505,
                1709874000
            ],
            [
                11.65,
                1710129600
            ],
            [
                11.88,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10018,
        "drug_name": "OTC NARCAN (naloxone HCl)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Opioid overdose",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-03-29",
        "link": "https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-over-counter-naloxone-nasal-spray",
        "note": "Approved March 29, 2023.",
        "company_entity_id": 123,
        "company_ticker": "EBS",
        "company_name": "Emergent Biosolutions Inc.",
        "company_price": "2.3300",
        "company_change": -0.47,
        "company_percent_change": -16.79,
        "company_optionable": 1,
        "company_number_of_shares": 52203433,
        "price_change_sparkline": [
            [
                1.67,
                1706677200
            ],
            [
                1.65,
                1706763600
            ],
            [
                1.62,
                1706850000
            ],
            [
                1.53,
                1707109200
            ],
            [
                1.56,
                1707195600
            ],
            [
                1.5,
                1707282000
            ],
            [
                1.68,
                1707368400
            ],
            [
                1.58,
                1707454800
            ],
            [
                1.8,
                1707714000
            ],
            [
                1.59,
                1707800400
            ],
            [
                1.69,
                1707886800
            ],
            [
                1.7,
                1707973200
            ],
            [
                1.56,
                1708059600
            ],
            [
                1.52,
                1708405200
            ],
            [
                2.71,
                1708491600
            ],
            [
                2.8,
                1708578000
            ],
            [
                2.74,
                1708664400
            ],
            [
                2.85,
                1708923600
            ],
            [
                3.3,
                1709010000
            ],
            [
                3.2,
                1709096400
            ],
            [
                3.23,
                1709182800
            ],
            [
                3.39,
                1709269200
            ],
            [
                3.17,
                1709528400
            ],
            [
                3.41,
                1709614800
            ],
            [
                3.26,
                1709701200
            ],
            [
                2.77,
                1709787600
            ],
            [
                2.69,
                1709874000
            ],
            [
                2.8,
                1710129600
            ],
            [
                2.335,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10280,
        "drug_name": "KEYTRUDA (pembrolizumab) injection",
        "clinical_trial_id": "NCT02460198",
        "has_trial_insight_page": 0,
        "indication": "adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-03-29",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/MRK\/news\/126333",
        "note": "FDA approval on March 29, 2023.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6405,
        "drug_name": "PADCEV (enfortumab vedotin) and KEYTRUDA (pembrolizumab) - (EV-103)",
        "clinical_trial_id": "NCT03288545",
        "has_trial_insight_page": 0,
        "indication": "Urothelial cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-04-03",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/SGEN\/news\/127392",
        "note": "FDA Approved on April 3, 2023.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10134,
        "drug_name": "Erleada (apalutamide)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Tablet reduction, non-metastatic castration-resistant prostate cancer (nmCRPC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-04-03",
        "link": "https:\/\/johnsonandjohnson.gcs-web.com\/static-files\/79a87563-654c-469e-abc1-7d4e0415f298",
        "note": "Approved April 3, 2023.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10297,
        "drug_name": "HYQVIA",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Primary immunodeficiency (PI) in children 2-16 years old",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-04-11",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/TAK\/news\/128659",
        "note": "Approved April 11, 2023.",
        "company_entity_id": 751,
        "company_ticker": "TAK",
        "company_name": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1\/2 of a share of)",
        "company_price": "14.3700",
        "company_change": -0.19999999999999996,
        "company_percent_change": -1.37,
        "company_optionable": 1,
        "company_number_of_shares": 3137776702,
        "price_change_sparkline": [
            [
                14.6,
                1706677200
            ],
            [
                14.38,
                1706763600
            ],
            [
                14.28,
                1706850000
            ],
            [
                13.92,
                1707109200
            ],
            [
                14.16,
                1707195600
            ],
            [
                14.18,
                1707282000
            ],
            [
                14,
                1707368400
            ],
            [
                14.24,
                1707454800
            ],
            [
                14.31,
                1707714000
            ],
            [
                14.34,
                1707800400
            ],
            [
                14.54,
                1707886800
            ],
            [
                14.42,
                1707973200
            ],
            [
                14.62,
                1708059600
            ],
            [
                14.82,
                1708405200
            ],
            [
                14.74,
                1708491600
            ],
            [
                14.64,
                1708578000
            ],
            [
                14.62,
                1708664400
            ],
            [
                14.81,
                1708923600
            ],
            [
                14.84,
                1709010000
            ],
            [
                14.65,
                1709096400
            ],
            [
                14.59,
                1709182800
            ],
            [
                14.56,
                1709269200
            ],
            [
                14.48,
                1709528400
            ],
            [
                14.4,
                1709614800
            ],
            [
                14.69,
                1709701200
            ],
            [
                14.86,
                1709787600
            ],
            [
                14.77,
                1709874000
            ],
            [
                14.57,
                1710129600
            ],
            [
                14.37,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9988,
        "drug_name": "RIZAFILM VersaFilm",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Acute migraine",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-04-17",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/IGXT\/news\/129789",
        "note": "Approved April 17, 2023.",
        "company_entity_id": 623,
        "company_ticker": "IGXT",
        "company_name": "IntelGenx Technologies Corp",
        "company_price": "0.1653",
        "company_change": 0,
        "company_percent_change": -0.47,
        "company_optionable": 0,
        "company_number_of_shares": 174658096,
        "price_change_sparkline": [
            [
                0.150855,
                1706677200
            ],
            [
                0.156,
                1706763600
            ],
            [
                0.1468,
                1706850000
            ],
            [
                0.1534,
                1707109200
            ],
            [
                0.16,
                1707195600
            ],
            [
                0.1505,
                1707282000
            ],
            [
                0.15,
                1707368400
            ],
            [
                0.143,
                1707454800
            ],
            [
                0.15,
                1707714000
            ],
            [
                0.1401,
                1707800400
            ],
            [
                0.1485,
                1707886800
            ],
            [
                0.145,
                1707973200
            ],
            [
                0.15,
                1708059600
            ],
            [
                0.155,
                1708405200
            ],
            [
                0.1458,
                1708491600
            ],
            [
                0.147575,
                1708578000
            ],
            [
                0.146545,
                1708664400
            ],
            [
                0.1452,
                1708923600
            ],
            [
                0.147845,
                1709010000
            ],
            [
                0.157,
                1709096400
            ],
            [
                0.15844,
                1709182800
            ],
            [
                0.157,
                1709269200
            ],
            [
                0.17,
                1709528400
            ],
            [
                0.15825,
                1709614800
            ],
            [
                0.1597,
                1709701200
            ],
            [
                0.1558,
                1709787600
            ],
            [
                0.177,
                1709874000
            ],
            [
                0.17,
                1710129600
            ],
            [
                0.165255,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5205,
        "drug_name": "Omisirge (omidubicel-onlv)",
        "clinical_trial_id": "NCT02730299",
        "has_trial_insight_page": 1,
        "indication": "Hematologic Malignancies",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-04-17",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/GMDA\/news\/129968",
        "note": "FDA Approved on April 17, 2023.",
        "company_entity_id": 607,
        "company_ticker": "GMDA",
        "company_name": "Gamida Cell Ltd.",
        "company_price": "0.3120",
        "company_change": -0.030000000000000027,
        "company_percent_change": -8.24,
        "company_optionable": 1,
        "company_number_of_shares": 132638514,
        "price_change_sparkline": [
            [
                0.3851,
                1706677200
            ],
            [
                0.365,
                1706763600
            ],
            [
                0.351,
                1706850000
            ],
            [
                0.3486,
                1707109200
            ],
            [
                0.3772,
                1707195600
            ],
            [
                0.3716,
                1707282000
            ],
            [
                0.3777,
                1707368400
            ],
            [
                0.3831,
                1707454800
            ],
            [
                0.38,
                1707714000
            ],
            [
                0.367,
                1707800400
            ],
            [
                0.381,
                1707886800
            ],
            [
                0.395,
                1707973200
            ],
            [
                0.407,
                1708059600
            ],
            [
                0.389,
                1708405200
            ],
            [
                0.3672,
                1708491600
            ],
            [
                0.3585,
                1708578000
            ],
            [
                0.3381,
                1708664400
            ],
            [
                0.38,
                1708923600
            ],
            [
                0.3821,
                1709010000
            ],
            [
                0.3658,
                1709096400
            ],
            [
                0.3596,
                1709182800
            ],
            [
                0.383,
                1709269200
            ],
            [
                0.3539,
                1709528400
            ],
            [
                0.36,
                1709614800
            ],
            [
                0.3505,
                1709701200
            ],
            [
                0.337,
                1709787600
            ],
            [
                0.3424,
                1709874000
            ],
            [
                0.34,
                1710129600
            ],
            [
                0.312,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10313,
        "drug_name": "QULIPTA (atogepant)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Preventive treatment of migraine",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-04-18",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ABBV\/news\/129994",
        "note": "Approved April 17, 2023.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7714,
        "drug_name": "Polivy (polatuzumab vedotin) - (POLARIX)",
        "clinical_trial_id": "NCT03274492",
        "has_trial_insight_page": 1,
        "indication": "Diffuse Large B-Cell Lymphoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2023-04-19",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/RHHBY\/news\/130589",
        "note": "FDA Approved on April 19, 2023.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    }
]